UCL has been placed 7th globally for medicine, 4th globally for pharmacy and pharmacology and 1st for education in the QS World University Rankings by Subject 2022.
High blood pressure and treatments to control it do not increase the risk of hospitalisation and death from Covid-19, according to a large European-wide study which in the UK was co-ordinated at UCLH and UCL.
Technology could be used to identify published scientific papers that have the greatest potential for real world impact – such as new medical treatments – according to UCL and UCLH research.
UCLH is to work in partnership with University Hospitals Birmingham NHS Foundation Trust in a major digital health initiative in which researchers use data collected in acute care settings to improve patient care.
Clinicians and research staff from across England and Wales attended patient and public involvement training delivered by the BRC between April 2021 and March 2022.
People without jobs or with less secure housing have poorer outcomes when treated for depression with talking therapy or antidepressants, compared to more socially advantaged peers, according to UCL led research.
A new artificial intelligence (AI) tool that can detect heart disease in record speed, helping to improve care for heart patients, is being rolled out at UCLH.
A single DNA test has been developed that can screen a patient’s genome for over 50 genetic neurological and neuromuscular diseases such as Huntington’s disease, muscular dystrophies and fragile X syndrome.
Two UCL and UCLH studies will look at whether analysis of advanced MRI scans can predict onset of multiple sclerosis and indicate which MS patients are at risk of developing irreversible disability.
The Clinical Research Facility at UCLH has been awarded £10 million in funding to deliver cutting edge early phase health research in areas including cancer and dementia.